Leiden — Myriagon has been announced as the winner of the Venture Challenge Fall 2025, a national programme that helps promising life-science start-ups validate their business case and prepare for growth. The award marks an important step for Myriagon and it highlights the strength of the joint innovation ecosystem built around Leiden University.

​

Tackling a major unmet need: safer treatment for neuropathic pain

​

Myriagon’s technology focuses on a new class of analgesics known as peripherally restricted MAGL inhibitors. These compounds have shown strong pain-relieving potential in preclinical models while not reaching the brain — a key limitation of many current neuropathic-pain treatments. Patients with neuropathic pain receive off-label medication, including opioids, that can lead to sedation, cognitive effects, or physical dependence. Myriagon aims to offer an effective, and safer alternative.

The Venture Challenge jury praised the company for its strong scientific foundation, convincing clinical rationale, and well-structured development strategy.

​

Powered by science: collaboration between Leiden University and Oncode Institute

​

Myriagon’s origins lie in academic research from Prof. Mario van der Stelt, and the team has benefited greatly from the combined scientific and translational expertise within Leiden University and the Oncode Institute.

​

The collaboration reflects the shared mission of Leiden University and Oncode Institute to translate fundamental discoveries into innovations that improve patient lives. Myriagon’s trajectory demonstrates how academic excellence, combined with structured translational support, can pave the way toward clinical impact.

​

Strengthening the regional life-sciences ecosystem

​

The win also shines a light on the broader Leiden Bio Science Park community, where academic institutions, research organisations, and start-ups closely interact. Together, Leiden University and Leiden Bio Science Park contribute to an environment where scientific findings can rapidly progress toward entrepreneurial ventures and biomedical innovation.

​

The €25,000 Venture Challenge award will help Myriagon further refine its development plan and prepare for the next phase.

​

Looking ahead

​

Myriagon work addresses a significant unmet need for millions of patients worldwide. The company’s success in the Venture Challenge illustrates what is possible when strong science, committed researchers, and robust academic support systems come together.

​

Leiden University looks forward to following Myriagon’s progress — and to seeing how this promising innovation may one day change the treatment landscape for neuropathic pain.